13F Data
13F filer · CIK 2104501

Remedium Capital Partners, LLC

WEST PALM BEACH, FL · filing since Q4 2025 · last filing Aug 7, 2026
Reported value
$451.6M
+$170.5M vs prior
Positions
6
New / sold out
1 / 1
Added / reduced
2 / 0
Turnover
1.8%
buys $7.6M · sells $6.6M
Top-10 weight
100.0%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewCrescent Biopharma Inc+361,250–+$6.5M
AddedSpyre Therapeutics Inc+7,938+0.5%+$704.7K
AddedApogee Therapeutics Inc+3,100+0.5%+$411.5K

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outCrescent Biopharma Inc-361,250-100.0%$-6.6M

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2025: $170.2MQ1 2026: $281.2MQ2 2026: $451.6M
Q4 2025Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1Oruka Therapeutics IncCOM1,565,661$149.0M32.99%
2Spyre Therapeutics IncCOM1,464,169$130.0M28.78%
3Apogee Therapeutics IncCOM586,691$77.9M17.24%
4Damora Therapeutics IncCOM2,045,473$53.2M11.78%
5Jade Biosciences IncCOM1,577,750$35.1M7.76%
6Crescent Biopharma IncCOM361,250$6.5M1.44%